GSK's Q4 2023 and full-year 2023 earnings released later this month are expected to continue showing strength, especially with the successful launch of Arexvy, its respiratory disease vaccine. However ...

GSK (GSK) is in advanced discussions to purchase privately-owned U.S. biotech IDRx, which is working on a treatment for rare gastrointestinal tumors, the Financial Times’ Oliver Barnes and Hannah ...

GSK recently reached a settlement in a lawsuit tied to Zantac, a product linked to cancer, but faces ongoing legal battles. The company's financial health remains strong, with a robust gross profit ...

GlaxoSmithKline ( ($GB:GSK) ) has issued an update. GSK plc has repurchased 235,000 of its ordinary shares on 18 December 2025 via BNP Paribas SA ...

British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, despite US tariffs, after sales of its cancer drugs jumped in the second quarter ...

An announcement from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK announced the recent purchase of 235,000 of its ordinary shares, as part ...

(Reuters) -Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times reported on Friday. Citadel has taken a short position worth 305 ...

March 1 (Reuters) - GSK (GSK.L), opens new tab CEO Emma Walmsley's total remuneration rose 51% to 12.7 million pounds ($16 million) in 2023, thanks to a big jump in performance-related pay, the ...

Valeo Financial Advisors LLC lowered its position in GSK plc (NYSE:GSK – Free Report) by 31.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and ...